Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice

Abigael Muchenditsi, Haojun Yang, James Hamilton, Lahari Koganti, Franck Housseau, Lisa Aronov, Hongni Fan, Hannah Pierson, Ashima Bhattacharjee, Robert Murphy, Cynthia Louise Sears, James John Potter, Clavia R. Wooton-Kee, Svetlana Lutsenko

Research output: Contribution to journalArticle

Abstract

Copper-transporting ATPase 2 (ATP7B) is essential for mammalian copper homeostasis. Mutations in ATP7B result in copper accumulation, especially in the liver, and cause Wilson disease (WD). The major role of hepatocytes in WD pathology is firmly established. It is less certain whether the excess Cu in hepatocytes is solely responsible for development of WD. To address this issue, we generated a mouse strain for Cre-mediated deletion of Atp7b and inactivated Atp7b selectively in hepatocytes. Atp7bHep mice accumulate copper in the liver, have elevated urinary copper, and lack holoceruloplasmin but show no liver disease for up to 30 wk. Liver inflammation is muted and markedly delayed compared with the age-matched Atp7b-/- null mice, which show a strong type1 inflammatory response. Expression of metallothioneins is higher in Atp7bHep livers than in Atp7b-/- mice, suggesting better sequestration of excess copper. Characterization of purified cell populations also revealed that nonparenchymal cells in Atp7bHep liver maintain Atp7b expression, have normal copper balance, and remain largely quiescent. The lack of inflammation unmasked metabolic consequences of copper misbalance in hepatocytes. Atp7bHep animals weigh more than controls and have higher levels of liver triglycerides and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. By 45 wk, all animals develop liver steatosis on a regular diet. Thus copper misbalance in hepatocytes dysregulates lipid metabolism, whereas development of inflammatory response in WD may depend on copper status of nonparenchymal cells. The implications of these findings for the cell-targeting WD therapies are discussed. NEW & NOTEWORTHY Targeted inactivation of copper-transporting ATPase 2 (Atp7b) in hepatocytes causes steatosis in the absence of inflammation.

Original languageEnglish (US)
Pages (from-to)G39-G49
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume313
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Fatty Liver
Copper
Hepatocytes
Obesity
Hepatolenticular Degeneration
Liver
Inflammation
Metallothionein
Lipid Metabolism
Liver Diseases
Oxidoreductases
Triglycerides
Homeostasis
Pathology
Diet
Mutation

Keywords

  • Copper
  • Copper-transporting ATPase 2
  • Hepatocytes
  • Obesity
  • Wilson disease

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice. / Muchenditsi, Abigael; Yang, Haojun; Hamilton, James; Koganti, Lahari; Housseau, Franck; Aronov, Lisa; Fan, Hongni; Pierson, Hannah; Bhattacharjee, Ashima; Murphy, Robert; Sears, Cynthia Louise; Potter, James John; Wooton-Kee, Clavia R.; Lutsenko, Svetlana.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 313, No. 1, 2017, p. G39-G49.

Research output: Contribution to journalArticle

Muchenditsi, Abigael ; Yang, Haojun ; Hamilton, James ; Koganti, Lahari ; Housseau, Franck ; Aronov, Lisa ; Fan, Hongni ; Pierson, Hannah ; Bhattacharjee, Ashima ; Murphy, Robert ; Sears, Cynthia Louise ; Potter, James John ; Wooton-Kee, Clavia R. ; Lutsenko, Svetlana. / Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2017 ; Vol. 313, No. 1. pp. G39-G49.
@article{39d208e9c687472a9e34ed9614c92ef5,
title = "Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice",
abstract = "Copper-transporting ATPase 2 (ATP7B) is essential for mammalian copper homeostasis. Mutations in ATP7B result in copper accumulation, especially in the liver, and cause Wilson disease (WD). The major role of hepatocytes in WD pathology is firmly established. It is less certain whether the excess Cu in hepatocytes is solely responsible for development of WD. To address this issue, we generated a mouse strain for Cre-mediated deletion of Atp7b and inactivated Atp7b selectively in hepatocytes. Atp7b∆Hep mice accumulate copper in the liver, have elevated urinary copper, and lack holoceruloplasmin but show no liver disease for up to 30 wk. Liver inflammation is muted and markedly delayed compared with the age-matched Atp7b-/- null mice, which show a strong type1 inflammatory response. Expression of metallothioneins is higher in Atp7b∆Hep livers than in Atp7b-/- mice, suggesting better sequestration of excess copper. Characterization of purified cell populations also revealed that nonparenchymal cells in Atp7b∆Hep liver maintain Atp7b expression, have normal copper balance, and remain largely quiescent. The lack of inflammation unmasked metabolic consequences of copper misbalance in hepatocytes. Atp7b∆Hep animals weigh more than controls and have higher levels of liver triglycerides and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. By 45 wk, all animals develop liver steatosis on a regular diet. Thus copper misbalance in hepatocytes dysregulates lipid metabolism, whereas development of inflammatory response in WD may depend on copper status of nonparenchymal cells. The implications of these findings for the cell-targeting WD therapies are discussed. NEW & NOTEWORTHY Targeted inactivation of copper-transporting ATPase 2 (Atp7b) in hepatocytes causes steatosis in the absence of inflammation.",
keywords = "Copper, Copper-transporting ATPase 2, Hepatocytes, Obesity, Wilson disease",
author = "Abigael Muchenditsi and Haojun Yang and James Hamilton and Lahari Koganti and Franck Housseau and Lisa Aronov and Hongni Fan and Hannah Pierson and Ashima Bhattacharjee and Robert Murphy and Sears, {Cynthia Louise} and Potter, {James John} and Wooton-Kee, {Clavia R.} and Svetlana Lutsenko",
year = "2017",
doi = "10.1152/ajpgi.00312.2016",
language = "English (US)",
volume = "313",
pages = "G39--G49",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice

AU - Muchenditsi, Abigael

AU - Yang, Haojun

AU - Hamilton, James

AU - Koganti, Lahari

AU - Housseau, Franck

AU - Aronov, Lisa

AU - Fan, Hongni

AU - Pierson, Hannah

AU - Bhattacharjee, Ashima

AU - Murphy, Robert

AU - Sears, Cynthia Louise

AU - Potter, James John

AU - Wooton-Kee, Clavia R.

AU - Lutsenko, Svetlana

PY - 2017

Y1 - 2017

N2 - Copper-transporting ATPase 2 (ATP7B) is essential for mammalian copper homeostasis. Mutations in ATP7B result in copper accumulation, especially in the liver, and cause Wilson disease (WD). The major role of hepatocytes in WD pathology is firmly established. It is less certain whether the excess Cu in hepatocytes is solely responsible for development of WD. To address this issue, we generated a mouse strain for Cre-mediated deletion of Atp7b and inactivated Atp7b selectively in hepatocytes. Atp7b∆Hep mice accumulate copper in the liver, have elevated urinary copper, and lack holoceruloplasmin but show no liver disease for up to 30 wk. Liver inflammation is muted and markedly delayed compared with the age-matched Atp7b-/- null mice, which show a strong type1 inflammatory response. Expression of metallothioneins is higher in Atp7b∆Hep livers than in Atp7b-/- mice, suggesting better sequestration of excess copper. Characterization of purified cell populations also revealed that nonparenchymal cells in Atp7b∆Hep liver maintain Atp7b expression, have normal copper balance, and remain largely quiescent. The lack of inflammation unmasked metabolic consequences of copper misbalance in hepatocytes. Atp7b∆Hep animals weigh more than controls and have higher levels of liver triglycerides and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. By 45 wk, all animals develop liver steatosis on a regular diet. Thus copper misbalance in hepatocytes dysregulates lipid metabolism, whereas development of inflammatory response in WD may depend on copper status of nonparenchymal cells. The implications of these findings for the cell-targeting WD therapies are discussed. NEW & NOTEWORTHY Targeted inactivation of copper-transporting ATPase 2 (Atp7b) in hepatocytes causes steatosis in the absence of inflammation.

AB - Copper-transporting ATPase 2 (ATP7B) is essential for mammalian copper homeostasis. Mutations in ATP7B result in copper accumulation, especially in the liver, and cause Wilson disease (WD). The major role of hepatocytes in WD pathology is firmly established. It is less certain whether the excess Cu in hepatocytes is solely responsible for development of WD. To address this issue, we generated a mouse strain for Cre-mediated deletion of Atp7b and inactivated Atp7b selectively in hepatocytes. Atp7b∆Hep mice accumulate copper in the liver, have elevated urinary copper, and lack holoceruloplasmin but show no liver disease for up to 30 wk. Liver inflammation is muted and markedly delayed compared with the age-matched Atp7b-/- null mice, which show a strong type1 inflammatory response. Expression of metallothioneins is higher in Atp7b∆Hep livers than in Atp7b-/- mice, suggesting better sequestration of excess copper. Characterization of purified cell populations also revealed that nonparenchymal cells in Atp7b∆Hep liver maintain Atp7b expression, have normal copper balance, and remain largely quiescent. The lack of inflammation unmasked metabolic consequences of copper misbalance in hepatocytes. Atp7b∆Hep animals weigh more than controls and have higher levels of liver triglycerides and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. By 45 wk, all animals develop liver steatosis on a regular diet. Thus copper misbalance in hepatocytes dysregulates lipid metabolism, whereas development of inflammatory response in WD may depend on copper status of nonparenchymal cells. The implications of these findings for the cell-targeting WD therapies are discussed. NEW & NOTEWORTHY Targeted inactivation of copper-transporting ATPase 2 (Atp7b) in hepatocytes causes steatosis in the absence of inflammation.

KW - Copper

KW - Copper-transporting ATPase 2

KW - Hepatocytes

KW - Obesity

KW - Wilson disease

UR - http://www.scopus.com/inward/record.url?scp=85021717392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021717392&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00312.2016

DO - 10.1152/ajpgi.00312.2016

M3 - Article

C2 - 28428350

AN - SCOPUS:85021717392

VL - 313

SP - G39-G49

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 1

ER -